Welcome to our dedicated page for Entera Bio news (Ticker: ENTX), a resource for investors and traders seeking the latest updates and insights on Entera Bio stock.
Entera Bio Ltd. (NASDAQ: ENTX) generates a steady flow of news as a clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies. News coverage on this page focuses on the company’s progress with its proprietary N-Tab™ oral peptide platform and its pipeline of tablet-based biologic candidates.
Investors and followers of ENTX can use this news feed to track key developments around EB613, Entera Bio’s lead oral PTH(1-34) (teriparatide) osteoanabolic tablet for postmenopausal women with osteoporosis or low bone mineral density. Updates often include Phase 2 clinical data, post-hoc analyses of bone mineral density outcomes, presentations at bone and endocrine conferences, and regulatory milestones such as FDA alignment on Phase 3 trial design and acceptance of total hip BMD as a primary endpoint.
The news stream also highlights progress in the EB612 program for hypoparathyroidism, including preclinical pharmacokinetic and pharmacodynamic data for a proprietary long-acting PTH analog formulated as a once-daily oral tablet. Coverage extends to Entera Bio’s collaboration with OPKO Health on oral GLP-2 and oxyntomodulin tablet candidates, with reports on preclinical data for short bowel syndrome and obesity programs presented at international nutrition and endocrine meetings.
In addition, readers will find quarterly financial results, business updates, participation in healthcare and investor conferences, and commentary from company leadership on strategy and clinical priorities. This page brings together ENTX press releases and related announcements so that investors, clinicians and other stakeholders can follow the company’s clinical, regulatory and collaboration milestones in one place.
Entera Bio Ltd. (NASDAQ: ENTX) will participate virtually in the H.C. Wainwright Global Investment Conference on September 15, 2020, at 3:00 p.m. EDT. Investors can access a live webcast of the presentation via the company’s website, with a replay available for 45 days after. Entera specializes in the development of orally delivered large molecule therapeutics for conditions like osteoporosis and hypoparathyroidism, leveraging proprietary technology to improve absorption and delivery. The company's candidates EB613 and EB612 are currently in Phase 2 clinical trials.
Entera Bio Ltd. (NASDAQ: ENTX) announced promising interim data from its Phase 2 clinical trial of EB613, an oral treatment for osteoporosis. The 6-month results demonstrated a mean placebo-adjusted increase of 2.15% in lumbar spine bone mineral density (BMD) for the 1.5 mg treatment group. With 131 subjects currently enrolled, the company expects to complete enrollment by Q3 2020. Financially, Entera reported revenues of $94,000 and an operating loss of $6.4 million for the first half of 2020, an increase from the previous year. Cash reserves stood at $9.8 million, sufficient to cover operations into Q2 2021.
Entera Bio Ltd. (NASDAQ: ENTX) will report its business and financial results for Q2 2020 on August 20, 2020, before U.S. markets open. A conference call is scheduled for 8:30 a.m. EDT on the same day, featuring management's discussion followed by a Q&A session. Participants can dial (855) 547-3865 (US) or (409) 217-8787 (international) with the ID '5243229'. Entera focuses on developing orally delivered large molecule therapeutics, including EB613 for osteoporosis and EB612 for hypoparathyroidism, both in Phase 2 trials.
Entera Bio Ltd. (NASDAQ: ENTX) announced its participation in the BTIG Biotechnology Conference on August 10, 2020, at 12:30 p.m. EDT. The event will be available via a live webcast on the company's Investor Relations page. A replay will be accessible for 45 days post-presentation.
Entera specializes in orally delivered macromolecule therapeutics addressing significant medical needs, particularly for patients who struggle with injectable therapies. Their leading candidates include EB613 for osteoporosis and EB612 for hypoparathyroidism, both in Phase 2 clinical development.
Summary not available.
Entera Bio Ltd. (NASDAQ: ENTX) reported significant progress in its Phase 2 clinical trial of EB613 for osteoporosis, with interim data showing statistically significant increases in the P1NP biomarker after one month of treatment. The 1.5 mg dose demonstrated notable improvement over placebo. The company plans to follow patients for six months to analyze bone mineral density data and explore higher doses for potential Phase 3 trials. Financially, Entera reported Q1 2020 revenue of $42,000 with a net loss of $(2.9) million, and cash reserves of $13.3 million, projected to last until mid-2021.
Entera Bio Ltd. (NASDAQ: ENTX) has announced it will release interim biomarker data from its Phase 2 osteoporosis clinical trial of EB613 and financial results for Q1 2020 on May 21, 2020, before the market opens. The first half of data will cover 50% of enrolled patients. A conference call will be held on the same day at 8:30 a.m. EDT to discuss findings and results, with a Q&A session to follow. Entera Bio focuses on developing orally delivered large molecule therapeutics, addressing unmet medical needs.